Malaysian Approval of FLEXISEQ™ and Distribution Agreement

Informations

• Publié par: pro-bono-bio
• Nombre de lectures: 34
• Langue: English

Extrait

Malaysian Approval of FLEXISEQ™ and

Distribution Agreement

PR Newswire

KUALA LUMPUR and LONDON, June 18, 2012

KUALA LUMPUR

and

LONDON

,

June 18, 2012

/PRNewswire/ --

New Osteoarthritis treatment for

Malaysia

Pro Bono Bio™ is pleased to announce that its innovative product FLEXISEQ, a

new nanotechnology based treatment for osteoarthritis, has received approval

for sale in

Malaysia

. This follows the successful launch of FLEXISEQ in

Europe

earlier this year.

Pro Bono Bio is also pleased to announce that they have signed an agreement

to distribute FLEXISEQ in

Malaysia

and the product will be available via local

distribution company, Farmasia Sdn. Bhd. from early

July 2012

. Its first

introduction to the local market is at the 42nd Annual Scientific Meeting of the

Malaysian Orthopaedic Association in Kuantan,

Malaysia

held between the 14

th

and 17

th

of

June 2012

.

Michael Earl, COO of Pro Bono Bio, said "Pro Bono Bio is an ambitious new

international pharmaceutical company which expects to make a real difference

for patients, doctors and payors alike by developing truly innovative products to

address areas of real need. It is a pleasure to launch our product FLEXISEQ

here in

Malaysia

following our success in

Europe

. We look forward to

introducing further innovative products this year and are also considering

where to site our regional headquarters and manufacturing facilities to support

our products in

South East Asia

."

Zohrah Razak Al Aidruss of Farmasia said "It is wonderful to have reached an

agreement to introduce such an innovative product into

Malaysia

. The unique

mode of action and lack of the side effects associated with various existing

drug products, makes this a very welcome addition to the solutions available for

physicians managing Osteoarthritis (OA). OA effects millions of patients in

Malaysia

, and both global and local trials have proved the effectiveness of

FLEXISEQ at relieving joint pain associated with OA."

About Pro Bono Bio™

Pro Bono Bio is a new international healthcare company based on the

experience in pharmaceutical product development, commercialisation and

finance of Celtic Pharma Holdings in the UK, international capital, along with

investment and support from RUSNANO in

Russia

. Pro Bono Bio has ambitious

growth targets that will allow it to support a unique humanitarian mission.

Pro Bono Bio launched its first medical device,

FLEXISEQ

, a new

nanotechnology based pain treatment for osteoarthritis, in

Europe

in the first

half of 2012. The Company also plans to launch two further new products for

the treatment of inflammatory skin disorders in the second half of 2012. These

new products are based on Pro Bono Bio's innovative

Sequessome

Technology™

.

Pro Bono Bio is also developing new products to treat haemophilia as well as

novel antibiotics for the treatment of serious infections such as C. difficile,

MRSA, Pneumonia and Tuberculosis.

http://www.probonobio.com

About FLEXISEQ

FLEXISEQ is the safe way to reduce joint pain associated with

osteoarthritis. FLEXISEQ

benefits from a Class 2A Medical Device

certification in

Europe

. It is a topically applied gel which uses the unique

Sequessome Technology

to pass through the skin and apply a biolubricant

layer inside the effected joint and along the cartilage. This improves the

mobility in the joint and reduces the pain.

http://www.flexiseq.com

For further information please contact:

Zohrah Ab Razak Al-Aidruss

[e-mail]

To order in

Malaysia

please contact:

Farmasia Sdn. Bhd.

[phone]

For

London

based press please contact:

Citigate Dewe Rogerson

David Dible / Nina Enegren

Tel: [phone]

[e-mail]